arrow
E

Eric Decloedt

stellenbosch university
H指数:23
被引数:2,383

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Pharmacokinetics of Efavirenz in Pregnancy and Postpartum with and Without First-line Tuberculosis Drugs: Results from IMPAACT P1026s

妊娠及产后期间使用和不使用一线结核病药物时依非韦伦的药代动力学:IMPAACT P1026s研究结果

2026-10-030
OA
Corrigendum to “Validated LC-MS/MS method for the quantification of glyphosate and its metabolites in human serum: A biomonitoring study in farming intensive regions of the Western Cape, South Africa” [Talanta 305 (2026) 129648]

勘误:关于“在南非西开普省农业密集区人体血清中草甘膦及其代谢物的量化验证LC-MS/MS方法:一项生物监测研究”[Talanta 305 (2026) 129648]

Talanta
IF6.1
2026-03-210
OAAI
Safety and potential efficacy of DM199, a tissue kallikrein-1 analogue, for treating pre-eclampsia and fetal growth restriction: study protocol for a South African, hospital-based phase I/II open-label trial

Cluver, C.A.; Thake, J.; Hassim, T.; van Greunen, A.; Budhram, S.; Knipe, K.; Decloedt, E.; Brink, L.; Langenegger, E.; Bergman, L.; et al. DM199(一种组织激肽释放酶-1类似物)治疗子痫前期和胎儿生长受限的安全性及潜在疗效:一项南非医院为基础的I/II期开放标签试验研究方案。BMJ Open 2025, 15, e104035. [Google Scholar] [CrossRef]

2025-12-160
OA
Association between antiretroviral therapy initiation or reinitiation timing and neuroimaging-confirmed stroke in people with HIV

抗逆转录病毒治疗启动或重新启动时间与HIV感染者神经影像学确诊卒中之间的关联

2025-11-250
OA
Pharmacokinetics and Safety of Clofazimine in Women With Rifampicin-resistant Tuberculosis During Pregnancy and the Postpartum Period: Results From IMPAACT P1026s

氯法齐明在利福平耐药结核病孕妇及产后妇女中的药代动力学与安全性:IMPAACT P1026s研究的结果

2025-10-010
PRE
A Real-Time Urine Tenofovir Assay Improves Drug Adherence Among People With HIV With Prior Virologic Failure in a Randomized Controlled Trial

实时尿液替诺福韦检测在随机对照试验中提高了具有既往病毒学失败史的人体免疫缺陷病毒感染者用药依从性

2025-07-010
OA
Pharmacokinetics and Safety of Levofloxacin for Treatment of Rifampicin-Resistant Tuberculosis During Pregnancy and the Postpartum Period: Results from IMPAACT P1026s

左氧氟沙星治疗利福平耐药结核病在孕期及产褥期的药代动力学与安全性:IMPAACT P1026s研究的结果

2025-03-280
OA
Pharmacokinetics and safety of first-line tuberculosis drugs rifampin, isoniazid, ethambutol, and pyrazinamide during pregnancy and postpartum: results from IMPAACT P1026s
2023-11-155
OA